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Extensive molecular characterization of human colorectal cancer (CRC) via Next
Generation Sequencing (NGS) indicated that genetic or epigenetic dysregulation of a
relevant, but limited, number of molecular pathways typically occurs in this tumor. The
molecular picture of the disease is significantly complicated by the frequent occurrence
of individually rare genetic aberrations, which expand tumor heterogeneity. Inter- and
intratumor molecular heterogeneity is very likely responsible for the remarkable individual
variability in the response to conventional and target-driven first-line therapies, in
metastatic CRC (mCRC) patients, whose median overall survival remains unsatisfactory.
Implementation of an extensive molecular characterization of mCRC in the clinical routine
does not yet appear feasible on a large scale, while multigene panel sequencing of most
commonly mutated oncogene/oncosuppressor hotspots is more easily achievable. Here,
we report that clinical multigene panel sequencing performed for anti-EGFR therapy
predictive purposes in 639 formalin-fixed paraffin-embedded (FFPE) mCRC specimens
revealed previously unknown pairwise mutation associations and a high proportion
of cases carrying actionable gene mutations. Most importantly, a simple principal
component analysis directed the delineation of a new molecular stratification of mCRC
patients in eight groups characterized by non-random, specific mutational association
patterns (MAPs), aggregating samples with similar biology. These data were validated
on a The Cancer Genome Atlas (TCGA) CRC dataset. The proposed stratification may
provide great opportunities to direct more informed therapeutic decisions in the majority
of mCRC cases.
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INTRODUCTION
Colorectal carcinoma (CRC) is one of the most commonly
diagnosed cancers worldwide (1, 2). A large proportion of
patients develop distant metastasis, which contributes to the high
mortality reported for this tumor. With the current standard
approaches, the 5-year survival rate for metastatic CRC (mCRC)
is about 13% (1–3). These oxaliplatin or irinotecan-based
chemotherapy regimens allow a median overall survival (OS) of
about 18–20 months (4, 5). Survival rates can be significantly
improved by a “triplet” approach consisting of 5-FU, oxaliplatin,
and irinotecan chemotherapy (6) and/or by the addition of
targeted drugs, such as monoclonal antibodies directed against
angiogenesis or EGFR pathway (7). Nonetheless, median OS
for mCRC rarely exceeds 30–36 months (8–10). Unfortunately,
individual responses to these therapeutic approaches may be
dramatically different from patient to patient reflecting the broad
inter- and intratumor molecular heterogeneity.
Historically, CRC represented the first model for multistep
cancer evolution in which discrete and sequential genetic
modifications in specific oncogenes and tumor-suppressor
genes occur throughout cancer progression (11, 12). Next
Generation Sequencing (NGS) provided significant advances in
understanding the molecular basis of CRC (13–15) and indicated
that genetic or epigenetic dysregulation of a relevant, but limited,
number of molecular pathways typically occurs in human CRC
(13, 15, 16). Thismolecular picture is complicated by the frequent
occurrence of individually rare genetic aberrations, which further
expand tumor heterogeneity (13–15).
Reflecting the different biology of CRCs, Guinney et al.
recently proposed a molecular classification in four consensus
molecular subtypes (CMS): CMS1-MSI immune, CMS2-
canonical, CMS3-metabolic, and CMS4-mesenchymal (13).
Although this might have implications for prognostication
and therapy decisions, its immediate transfer to routine
diagnostic/clinical settings is seriously challenging in terms of
methodology, turnaround time, costs, and mindset. In fact,
despite NGS and other omic approaches may disclose a huge
amount of molecular details, still very few of them have yet
acquired clinical relevance. In example, the use of anti-EGFR
therapy is essentially dictated by the RAS (KRAS+NRAS) wild
type status, in the clinical routine (17, 18), which however
is largely insufficient for the positive selection of responsive
patients (19, 20). Treatment with anti-VEGF antibodies is not
driven by specific selection criteria due to lack of validated
molecular biomarkers (21, 22). Other targeted approaches (i.e.,
BRAF or PI3K inhibitors used as single agents) failed due to
resistance mechanisms (23). These evidences support the need
for a paradigm shift in personalized medicine, as suggested by
Dienstmann et al. (24): from a one-gene one-drug approach, to a
multi-gene multi-drug perspective.
The use of multigene panel sequencing has been recently
validated for clinical applications. In example, we introduced
a 22 multigene panel sequencing, which includes the clinically
relevant RAS and BRAF hotspots, as a routine for the predictive
selection of mCRC patients to be subjected to anti-EGFR therapy
(25–32). This implementation allowed us to accumulate a large
dataset to ask the question of whether application of multigene
panel sequencing to the standard diagnostics of mCRC could
provide clinically useful information, with no extra-costs in terms
of turnaround time and money.
On the basis of results obtained on 639 formalin-fixed and
paraffin-embedded (FFPE) tumor samples, here we report that
clinical genomic profiling with a multigene panel identifies
distinct molecular association patterns (MAPs) and provides
great opportunities to unveil co-occurrence of actionable gene
mutations to direct more appropriate therapeutic decisions for
the majority of mCRC patients.
PATIENTS AND METHODS
Specimen Collection
A total of 779 FFPE tumor samples from mCRC patients were
collected from Policlinico Umberto I (Rome, Italy) and from
the Department of Public Health, University Federico II, Naples,
Italy. The large majority of samples (696/779) were from the
primary site, while few (83/779) were from metastatic sites. All
samples reached the molecular pathology labs with a medical
prescription for determination of RAS/BRAF mutation status for
predictive purposes. As such, only scattered clinical-pathological
information was available for the two series. For this retrospective
observational study all investigations were approved by the
Ethics Committee of the University La Sapienza (Prot.: 88/18;
RIF.CE:4903, 31-01-2018). All information regarding human
material included in the study was managed using anonymous
numerical codes, and all samples were handled in compliance
with the principles outlined in the declaration of Helsinki. For
samples collected at the Department of Public Health, University
Federico II, we obtained written informed consent from all
patients, in accordance with the general authorization to process
personal data for scientific research purposes from “The Italian
Data Protection Authority (http://www.garanteprivacy.it/web/
guest/home/docweb/-/docwebdisplay/export/2485392).
DNA Extraction
Tissue samples with a content of tumor-vs.-non-tumor cells
below 20% (evaluated at the observation of Hematoxylin and
Eosin stained slides) were excluded from the analysis (33). The
tumor area was macroscopically dissected to concentrate tumor
tissue. Xylene was added once and ethanol was added twice
to remove all paraffin from the tissue sample (34). DNA was
extracted using QIAamp DNA FFPE Tissue kit (Qiagen GmbH,
Hilden, Germany) according to the manufacturer’s instructions.
Eluted DNAwas quantified with Qubit 2.0 Fluorometer (Thermo
Fisher Scientific, Van Allen Way, Carlasbad, CA 92008, USA)
using QubitTM dsDNA HS Assay Kit (Thermo-Fisher Scientific,
Eugene, Oregon 96492, USA).
IT-PGM Sequencing and Variant Calling
IT-PGM sequencing was achieved as described (25, 27, 35).
Approximately, 10 ng of DNA samples was required to construct
barcoded and adaptor-ligated libraries using the Ion AmpliSeq
Library kit 2.0 (Thermo Fisher Scientific, Van Allen Way,
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Carlsbad, CA 92008 USA) and Ion Xpress Barcode Adapter 1-
16 Kit (Thermo Fisher Scientific, Van Allen Way, Carlsbad, CA
92008 USA). The samples were analyzed using Ion AmpliSeq
Colon and Lung Cancer Research Panel V2 (CLV2, Thermo
Fisher Scientific, Guilford, CT 06437, USA) containing a single
primer pool to amplify hotspots and targeted regions of 22
cancer genes frequently mutated in CRCs and NSCLCs (29).
Templated spheres were prepared using 100 pM of each library
using the Ion One Touch 2.0 machine (Thermo Fisher Scientific,
Van Allen Way, Carlsbad, CA 92008 USA). Template-positive
spheres were loaded into Ion chip 314 or Ion chip 316 and
sequenced by IT-PGM machine (Thermo Fisher Scientific, Van
Allen Way, Carlsbad, CA 92008 USA). Sequencing data were
analyzed with the Ion Torrent Suite (Thermo Fisher Scientific,
http://github.com/iontorrent/TS). Variants with a quality <30
were filtered out.
For the purpose of the study, we generated a mutational data
set including only samples carrying mutations of established
clinical relevance for KRAS (mutations at codon 12, 13, 59, 61,
117, and 146), BRAF (V600E) and PIK3CA (mutations in exon
10 and 21). For TP53, we included in the study samples carrying
mutations with defined pathogenic significance according to
ClinVar and/or well-established hotspot mutations. We excluded
from the study 140 samples carrying variants of unknown
clinical significance (VUS) in these genes. For all other genes,
we listed all genetic alterations described as pathogenic, likely-
pathogenic or predicted deleterious by in silico analysis, while
benign polymorphisms were not considered.
When appropriate, PolyPhen-2 (Polymorphism Phenotyping
v2; http://genetics.bwh.harvard.edu/pph2/), PROVEAN/SIFT
(Sort Intolerant From Tolerant Subsitutions) http://provean.jcvi.
org/protein_batch_submit.php?species=human) computational
tools were used to predict the possible impact of the detected
alterations on the structure and function of the protein (18, 19).
The reference sequence used are: KRAS NM_033360.3, TP53
NM_000546.5, PIK3CA NM_006218.3, BRAF NM_004333.4,
NRAS NM_002524.4, FBXW7 NM_033632.3, SMAD4
NM_005359.5, PTEN NM_000314.6, MET NM_001127500.2,
STK11 NM_000455.4, EGFR NM_005228.4, CTNNB1
NM_001904.3, AKT1 NM_001014431.1, ERBB2 NM_004448.3,
ERBB4 NM_005235.2, FGFR1, NM_001174063.2, ALK
NM_004304.4, MAP2K1 NM_002755.3, NOTCH1
NM_017617.4, DDR2 NM_001014796.3, FGFR3 NM_000142.4,
FGFR2 NM_000141.4.
MSI Analysis
Determination of MSI status was investigated on 162 patients
(72 of the 639 cases representing the main bulk of the study
plus 90 additional cases collected at a later stage and analyzed
separately). It was carried out by analysis of BAT25, BAT26,
NR21, NR22, and NR24 mononucleotide repeats as previously
described (36). Briefly, one PCR primer of each pair was labeled
with 1 with either FAM, HEX, or NED fluorescent markers. PCR
amplification was performed under the following conditions:
denaturation at 94◦C for 5min, 35 cycles of denaturation at 94◦C
for 30 s, annealing at 55◦C for 30 s, and extension at 72◦C for
30 s. This was followed by an extension step at 72◦C for 7min.
PCR products were run on ABI PRISM 3130xl Genetic Analyzer
(16 capillary DNA sequencer, Applied Biosystem). Gene Mapper
software 5 (version 5.0, Applied Biosystems, Van Allen Way,
Carsvad, CA 92008, USA) was used to calculate the size of each
fluorescent PCR product.
Statistical Analysis
The mutational data set was organized in a matrix composed
by 20 columns and 639 rows where each row corresponds to
a different sample and each column corresponds to one of
22 different genes whose mutational pattern was characterized.
We performed a Principal Component Analysis (PCA) on this
mutational dataset in order to classify mutational patterns based
on their similarity. Each matrix element Mij (where i is a generic
sample and j is a generic gene) can assume the value 0 or 1 if
the patient i has no mutation in the gene j or the mutation is
present, respectively (37). Each principal component is a linear
combination of optimally-weighted original variables, and so it
is often possible to ascribe meaning to what the components
represent. The statistical analysis was carried out with SPSS
statistics or standard R software, version 2.13.1 (http://www.r-
project.org).
Statistical analyses on gender, tumor type, tumor location,
and MSI-H phenotype were performed on all cases for which
appropriate information was available, using both the 639 and the
90 series.
The Pearson’s Chi-square test and Fisher’s exact test of
association was used to determine the relationship between
two categories which consist in coexistence of two mutations
(pairwise association analysis). A p < 0.05 was considered
statistically significant.
TCGA Network Data set
We downloaded gene somatic mutations for 625 patients from
the TCGA data portal (https://portal.gdc.cancer.gov/) accessed
December 2018 (38, 39). We cleared this dataset from samples
carrying VUS, as we did for our dataset (see above). The resulting
data set contained 412 patients with their mutational data of the
22 genes included in the CLV2 panel.
We employed the R package TCGAbiolinks (40) to retrieve
patient’s Microsatellite Instability (MSI) status from the legacy
archive of GDC data portal (https://portal.gdc.cancer.gov/).
RESULTS
Mutation Profiling of mCRCs, Pairwise
Associations, and Identification of
Actionable Targets
Using a 22 gene panel NGS approach, we detected pathogenic
mutations in at least one of the 22 targets in 523 out of
639 (81.8%) mCRC samples (Table S1). Mutation spectra and
frequencies were in line with previous reports (14, 15, 31)
(Figure 1A). Eleven genes displayed a mutation frequency
>1.5% (mutation number >10), being TP53 and KRAS the
most frequently mutated genes (48.5 and 39.4%, respectively)
(Figure 1A). Mutations occurred less frequently (<1.5%) in the
other 11 genes (CTNNB1, AKT1, ERBB2, ERBB4, FGFR1, ALK,
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FIGURE 1 | Mutation frequencies and pairwise associations. (A) Mutation rates (and absolute numbers of the bars) in 639 metastatic colorectal cancers. (B)
Correlation Plot describing pairwise association of the mutations occurring on the 11 genes with a mutation frequency >1.5% (mutation number >10). Statistical
analysis is given Table 1. *p < 0.05.
MAP2K1,NOTCH1,DDR2, FGFR3, and FGFR2), consistent with
the “tail effect” associated with NGS profiling of tumor samples
(15) (Figure 1A).
To investigate on mutation associations, we initially
performed a pairwise association analysis for those genes with
a mutation frequency >1.5%. In agreement with previous
literature, BRAF, KRAS, NRAS mutations were mutually
exclusive, while PIK3CA and FBXW7 mutations frequently
occurred in association with KRAS mutations. BRAF and
SMAD4 mutations were associated, while TP53 and KRAS
mutations were negatively associated (Figure 1B, Table 1). We
also revealed previously unreported positive association between
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TABLE 1 | Significant pairwise associations between most frequent gene
mutations.
Genea Status Wt (%) Mut (%) pb References
KRAS (%)
TP53 Mut 200 (51.7) 110 (43.7) 0.047 (44)
PIK3CA Mut 38 (9.8) 61 (24.2) <0.001 (43)
BRAF Mut 50 (12.9) 1 (0.4) <0.001 (43)
NRAS Mut 30 (7.8) 1 (0.4) <0.001 (43)
FBXW7 Mut 20 (5.2) 23 (9.1) 0.05 (31)
EGFR Mut 3 (0.8) 8 (3.2) 0.03* New
PIK3CA (%)
FBXW7 Mut 31 (5.7) 12 (12.1) 0.02 (45)
BRAF (%)
SMAD4 Mut 23 (3.9) 6 (11.8) 0.022* (46)
PTEN Mut 18 (3.1) 5 (9.8) 0.03* New
EGFR (%)
SMAD4 Mut 26 (4.1) 3 (27.3) 0.011* New
TP53 (%)
NRAS Mut 9 (2.7) 22 (7.1) 0.01 New
aThe genes with an overall mutational rate higher than 1.5% (number of mutations >10)
were considered for statistical analysis. bChi-squared test.
*Fisher exact test.
EGFR mutations and KRAS and SMAD4 mutations, while BRAF
mutations were significantly associated with PTEN mutations
(Figure 1B, Table 1, Table S2). At variance from KRAS, NRAS
mutations were significantly associated with TP53mutations.
Overall, 374/639 (58.5%) patients carried actionable gene
mutations, as defined by Chakravarty et al. (41), and 153 patients
carried druggable alterations. Importantly, the vast majority of
patients positive or negative for specific actionable mutations
frequently carried additional relevant genetic alterations
(Table 2), which in principle could contribute to an individual
variability in patients’ responsiveness to standard and target-
driven therapies. In example, only 27 (4.2% of the entire series)
of the 99 patients carrying PIK3CA mutations were RAS/BRAF
WT and only 9 of these (1.4% of the entire series) harbored
exclusively PIK3CA mutations. On the same line, 17/639 (2.7%)
patients carried only BRAF mutations, while 34 BRAF mutant
samples also carried additional mutations.
Identification of Mutational Association
Patterns (MAPs)
Although pairwise associations might provide interesting
insights into the molecular nature of CRC and represents a
step forward in considering the molecular complexity of cancer
for prognostic and predictive purposes, we reasoned that a
more comprehensive use of the entire mutational profile of
each sample could help defining a novel and more precise
classification of CRC.
Thus, we subjected our large dataset to a principal component
analysis (PCA) with the aim to detect those genes which
better classify the different samples based on their overall
mutational profile. This approach clearly indicated that two
TABLE 2 | Frequency of co-mutation in genes carrying actionable mutations.
Status No. of pts. (%) No. of pts. (%) with
additional mutations
KRAS WT 387 (60.6) 270 (42.2)
Mut 252 (39.4) 176 (27.5)
NRAS WT 608 (95.2) 491 (76.8)
Mut 31 (4.8) 26 (4.1)
BRAF WT 588 (92.0) 471 (73.7)
Mut 51 (8.0) 34 (5.3)
PIK3CA WT 540 (84.5) 423 (66.2)
Mut 99 (15.5) 89 (13.9)
EGFR WT 629 (98.4) 512 (80.1)
Mut 10 (1.6) 9 (1.4)
MET WT 633 (99.1) 516 (80.7)
Mut 6 (0.9) 6 (0.9)
PTEN WT 618 (96.7) 501 (78.4)
Mut 21 (3.3) 20 (3.1)
AKT1 WT 634 (99.2) 517 (80.9)
Mut 5 (0.8) 4 (0.6)
ERBB2 WT 636 (99.5) 519 (81.2)
Mut 3 (0.5) 3 (0.5)
ALK WT 638 (99.8) 521 (81.5)
Mut 1 (0.2) 1 (0.2)
MAP2K1 WT 638 (99.8) 521 (81.5)
Mut 1 (0.2) 1 (0.2)
genes (TP53 and KRAS) could sharply cluster our samples into
four different subsets:TP53wt/KRASwt samples,TP53mut/KRASwt
samples, TP53wt/KRASmut samples, and TP53mut/KRASmut
samples (Figure 2). While mutations in other genes could also
aggregate our samples into distinct subsets (see for example
PIK3CA and BRAF, Figure 2), they never reached the sharp
effectiveness of TP53 and KRASmutations.
Thus, in accordance to PCA results, we stratified the 639
CRC cases into four different mutation association patterns
(MAPs) based on TP53 and KRAS mutation status (Figure 3A).
Depending on the presence/absence of mutations in genes other
than TP53 and KRAS, each MAP could be further divided in two
subsets leading to delineation of a total of eight different MAPs
(Figure 3A).
This stratification promptly revealed that 18.2% of the samples
carried nomutations in any of the 22 gene of the panel (MAP4.2),
while 29.4% harbored only one mutation in either KRAS or TP53
(MAP2.2 and MAP3.2, respectively). An additional 11.6% of the
patients only carried KRAS and TP53 mutations with no other
alterations (MAP1.2), which indicates that a large fraction of the
mCRC cohort is characterized by a very low mutation rate, as
detectable by our gene panel sequencing.
The distribution of mutations in genes other than TP53
and KRAS also occurred non-randomly among the MAPs
(Figures 3A,B) clearly defining distinct molecular profiles.
Indeed, the Pearson’s Chi-square test and Fisher’s exact test
showed statistical significance for almost all the comparisons
between the MAPs (Table S3). In details, the eight MAPs are
characterized as follows.
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FIGURE 2 | Principal component analysis indicates that four different subsets of mCRC samples may be sharply identified based on KRAS and TP53 mutation status.
Principal-component analysis of the sequencing results of 639 mCRCs indicates that the most represented genes in the first two principal components (PC) are able
to better separate the data according to their variation. PC1 and PC2 contain 51% of variation in the data. KRAS, TP53, PIK3CA, and BRAF genes have been
identified as the most important genes of PC1 and PC2. Each mutational profile has been projected in a two-dimensional space using the PC1 and PC2 to help
appreciate sample separation. Each graph indicates how PCA analysis assembles patients (dots) in four distinct groups distinguishable in the two-dimensional space.
Red dots, green dots, blue dots, and magenta dots represent samples with mutations in p53, KRAS, PIK3CA, or BRAF, respectively. While KRAS and TP53 mutations
sharply map in the four distinct groups in the two dimensional-space, both PIK3CA and BRAF mutations are much less efficient in defining the identity of the four
groups, thus indicating that the formers are more effective in creating sharp group separation.
MAP1.1. This MAP, characterized by the TP53mut/KRASmut
status, showed a high rate of PIK3CA mutations
(52.8%), rare (2.8%) BRAFV600E mutations and no NRAS
alterations. We also found a relevant number of FBXW7
mutations (27.8%), and some PTEN (11.1%) and SMAD4
mutations (8.3%), most often mutually exclusive with
PIK3CAmutations.
MAP1.2. This MAP was characterized by the
TP53mut/KRASmut status, and no additional mutations.
MAP2.1. This MAP, characterized by TP53wt/KRASmut status,
showed the highest frequency of PIK3CA mutations (62.7%).
Intriguingly, 3 out of 5 E17K AKT1 mutations occurred in
PIK3CA WT samples in this MAP, concurring to the activation
of the same pathway.
A fair amount of FBXW7 mutations (19.4%) and a few
SMAD4 mutations (9.0%), but no BRAF and rare NRAS
mutations (1.5%) occurred in MAP2.1. Coherent with the
previously mentioned KRAS pairwise association, the rare EGFR
mutations clustered in MAP1.1 and MAP2.1.
MAP2.2.ThisMAPwas characterized by theTP53wt/KRASmut
status, and no additional mutations.
MAP3.1. This MAP, characterized by TP53mut/KRASwt status,
had a high frequency of BRAF (20.5%), combined with
the highest frequency of NRAS (in a mutually exclusive
way) and SMAD4 mutations (25.0 and 18.2%, respectively).
This group also showed PIK3CA mutations in 23.9% of the
samples, at least partially non-overlapping with BRAF, NRAS,
and SMAD4 mutations, and the lowest frequency of FBXW7
mutations (5.7%).
MAP3.2.ThisMAPwas characterized by theTP53mut/KRASwt
status, and no additional mutations.
MAP4.1. In thisMAP, characterized by TP53wt/KRASwt status,
we found the highest frequency of BRAF mutations (45.1%) and
the lowest amount of SMAD4 mutations (5.6%). It also showed
mutations in PIK3CA, NRAS, and FBXW7, respectively, in 23.9,
11.3, and 21.1% of the samples.
MAP4.2. This MAP was characterized by absence
of mutations.
Importantly, the analysis of microsatellite instability (MSI)
on a test group of 162 samples revealed that 9 tumors were
MSI-H. 6 out of 9 MSI-H samples clustered into MAP4.1, 2 in
MAP3.1 and 1 in MAP4.2 (Table 3), which suggests that the
proposed mutational stratification is able to aggregate samples
with similar biology.
Mutation distribution of other genes did not vary significantly
among MAPs and/or was too low to support major conclusions.
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FIGURE 3 | Mutation Association Patterns of the 639 mCRC samples according to the 22 gene panel analysis. (A) The presence of a mutation is depicted with a
specific color for each gene, while the absence is indicated in white. Four main patterns are obtained, depending on KRAS and TP53 status: MAP1, MAP2, MAP3,
and MAP4. Depending on the presence/absence of mutations in genes other than TP53 and KRAS, each MAP could be further divided in two subMAPs (MAP1.1,
MAP1.2, MAP 2.1, MAP 2.2, MAP 3.1, MAP 3.2, MAP 4.1, MAP 4.2). (B) The frequency of mutation in PIK3CA, BRAF, NRAS, FBXW7, SMAD4, and PTEN genes in
the four subMAPs is reported. The Pearson’s Chi-square test or Fisher’s exact test were carried out and shown in Table S3.
Identification of MAPs on the TCGA
Dataset
To validate MAPs in an external dataset, we accessed the TCGA
public mutational data for CRC patients. After appropriate
curation of the dataset in order to select all pathogenic mutations
potentially identifiable by our multigene panel sequencing
approach, we had 412 samples available for MAP stratification.
Of interest, the TCGA dataset included all CRC stages, and only a
minority of the cases were mCRC (Figure S1A), as already noted
by others (14, 42).
The mutation frequencies on the 22 genes included in the
CLV2 panel were largely similar between TCGA dataset and our
mCRC cohort (Figure S1B). All different MAPs exist with rather
similar rates, in TCGA dataset and our series, with MAP 4.1
and MAP4.2 representing sharp exceptions. Indeed, MAP 4.1
accounts for 11.1% of our series of mCRC samples, compared to
18.0% of the TCGA dataset, while MAP4.2 accounts for 18.2%
in our series and 5.3% of the TCGA dataset. At variance from
our cohort, TCGA dataset included 14% of MSI-H samples,
which is consistent with its stage 1-to-stage 4 composition
(14). The majority of these cases clustered in MAP4.1, possibly
providing an explanation for the different MAP4 rates between
the two datasets.
PIK3CA, BRAF, and NRAS mutation rates in the different
MAPs display similar trends in our metastatic cohort and in the
TCGA dataset (Figures S2A,B). We observed less consistency for
themutation rates of the less frequently mutated FBXW7, SMAD,
and PTEN genes.
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TABLE 3 | Associations between selected features and MAPs.
MAPs
No. % 1.1 1.2 2.1 2.2 3.1 3.2 4.1 4.2 p
Gender M 346 60.1 29 (8.40%) 44 (12.7%) 35 (10.1%) 37 (10.7%) 44 (12.7%) 64 (18.5%) 34 (9.8%) 59 (17.1%) 0.301
F 230 39.9 15 (6.5%) 37 (16.1%) 28 (12.2%) 26 (11.3%) 41 (17.8%) 33 (14.3%) 22 (9.6%) 28 (12.2%)
Site Rectum 89 15.5 9 (10.1%) 14 (15.7%) 17 (19.1%) 5 (5.6%) 9 (10.1%) 13 (14.6%) 6 (6.7%) 16 (18.0%) 0.058
Colon 486 84.5 35 (7.2%) 67 (13.8%) 46 (9.5%) 58 (11.9%) 76 (15.6%) 84 (17.3) 50 (10.3%) 70 (14.4%)
Side Right 183 55.3 12 (6.6%) 31 (16.9%) 23 (12.6%) 18 (9.8%) 36 (19.7%) 15 (8.2%) 34 (18.6%) 14 (7.7%) <0.0001
Left 148 44.7 12 (8.10%) 17 (11.5%) 15 (10.1%) 19 (12.8%) 24 (16.2%) 36 (24.3%) 3 (2.0%) 22 (14.9%)
MSI absent 153 94.4 19 (12.4%) 31 (20.3%) 20 (13.1%) 14 (9.2%) 25 (16.3%) 24 (15.7%) 3 (2.0%) 17 (11.1%) *<0.0001
present 9 5.6 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 2 (22.2%) 0 (0.0%) 6 (66.7%) 1 (11.1%)
*Fisher’s exact test. Bold: statistically significant.
Correlation Between Clinical-Pathological
Features and MAPs
Next, we examined how MAP stratification correlated with
gender and tumor site, the only variables we had available for
a reasonable number of patients (Table 3). MAP stratification
did not significantly correlate with gender. Concerning tumor
site, differences in MAP distribution between colon and rectal
localization were close to statistical significance, with a trend
for MAP2.1 to be more represented and for MAP2.2 and
MAP3.1 to be less represented in rectum compared to colon
cancer (Table 3). Moreover, while MAP1 and MAP2 have similar
frequencies among right-side and left-side CRC, MAP3.2 and
MAP4.2 (accounting for by samples with no mutations or TP53
mutations only) were overrepresented in left-side CRC, and
MAP4.1 was overrepresented in right-side CRC. Of relevance, the
association ofMAP 4.1 with right side remains significant even by
omitting MSI-H cases (not shown).
DISCUSSION
The response of mCRC to current therapeutic approaches is
highly variable, reflecting the elevated heterogeneity of the
disease (7). This, together with an increasing availability of
targeted therapeutic approaches, stresses the need for more
comprehensivemolecular characterization of each tumor sample,
in order to push forward the real achievement of personalized
interventions. Despite it is clear that an extended molecular
characterization of CRC patients may significantly impact on
their clinical management (27–30), very little has entered the
clinical routine, yet.
Here, we report that a clinical genomic profiling via
multigene panel sequencing allowed identification of pairwise
mutation associations and eight distinct MAPs, providing great
opportunities to direct more informed therapeutic decisions, in
the majority of mCRC cases.
Our data confirm previously reported pairwise gene
mutation associations (31, 43–46) and unveil for the first time
EGFR/KRAS, EGFR/SMAD4, BRAF/PTEN, and NRAS/TP53
positive associations. The biological or clinical meaning of these
associations is difficult to trace, at the moment. In example, while
mutations in the EGFR tyrosine-kinase domain are mutually
exclusive with KRAS mutations and are positive predictive
biomarkers for the efficacy of tyrosine kinase inhibitors in
non-small cell lung cancer (NSCLC) (34, 47), these mutations are
rare and scarcely relevant in predicting responses to antibody-
based anti-EGFR therapy, in mCRC (48). 8/11 EGFR mutation
occurring in our mCRC cohort coexist with KRAS mutations.
On one side, this may imply that coexisting EGFR and KRAS
activating mutation might provide additional advantages to
tumor progression in mCRC. This is also supported by the
frequent co-occurrence of KRAS and PIK3CA, leading to the
constitutive activation of two different pathways downstream
of the EGFR. Alternatively, EGFR and KRAS mutations could
also exist in different subclonal mCRC populations in the
same tumor, as a result of tumor heterogeneity, driving the
activation of the same pathway. Addressing the details of
tumor heterogeneity and clonality, by tumor multisampling
and/or single cell sequencing, will be required to address
these issues.
Clinical multigene panel sequencing may easily lead to
the identification of actionable and targetable gene mutations
(27–31). More importantly, it provides awareness that specific
actionable/targetable mutations most frequently co-occur with
additional relevant genetic alterations, which in principle could
contribute to an individual variability in patients’ responsiveness
to standard and target-driven therapies. Overlooking this
molecular complexity may account for treatment failures, when
approved or innovative targeted approaches are used. The scant
success of PI3K inhibitors in mCRC may be at least in part due
to PIK3CA mutations co-occurring with RAS/BRAF mutations
(more than 70% of the PIK3CAmut patients in our cohort) (49).
It cannot be excluded that other gene mutations (occurring in an
additional 18% of the PIK3CAmut patients in our cohort) may
also provide primary resistance to PI3K inhibitors. Only 1.4% of
our entire cohort carried exclusively PIK3CAmutations, possibly
underscoring a subset of patients best suited for treatment with
PI3K inhibitors. On the same line, 2.7% (17/639) of the patients
carried only BRAF mutation, possibly representing the best
subset for a target treatment with BRAFV600E inhibitors alone, or
in combination with anti-EGFR (50, 51). Most patients carrying
BRAFV600E also carried additional mutations, at least some of
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FIGURE 4 | Molecular association pattern taxonomy and potential implications for therapies.
which might be expected to be involved in primary resistance to
anti-BRAF therapies, providing contraindication to single target
approaches. In line with this, a phase III 3-arm trial is currently
exploring the effectiveness of a triplet therapy with the BRAF
inhibitor plus MEK inhibitor associated with the anti EGFR
antibody CETUXIMAB in BRAFV600E mCRC, in the second or
third-line setting (BEACON CRC NCT02928224) (23).
Most importantly, we believe that the greatest added value
of clinical multigene panel sequencing may come from a more
comprehensive use of the entiremutational profile of each patient
to implement a more precise molecular stratification of mCRC.
In this observational study, we developed a new stratification
system into eight distinct MAPs characterized by non-random,
specific mutational combinations. We validated these findings
via TCGA data analysis, although few interesting differences
emerged. In particular, the different rate of MSI-H cases and
the different size of MAP4.1 may be due to the different stage
composition between our cohort and TCGA dataset. Whether
this is also relevant for the different size of MAP4.2 and the
different distribution of some less frequently mutated genes
remains to be determined.
Although we are aware that the lack of clinical data only allows
for a speculative proposition, we believe that our comprehensive
molecular stratification may provide the base for informed
therapeutic decisions, for the majority of mCRC patients, as
detailed below (Figure 4).
Firstly, about 50% of our cohort bears no mutations at all
(MAP4.2) or just one mutation (MAP2.2 and MAP3.2). An
additional 11.6% of patients is characterized bymutations limited
to KRAS and TP53 (MAP1.2). Even considering the almost
ubiquitous activation of the WNT pathway due to mutations
in APC, β-catenin or RNF43 genes (14), these data suggest
that the majority of mCRC develop and progress with a low
mutation load, which has significant implications for therapeutic
interventions. Of interest, the little representation of MAP4.2 in
the mixed-stages TCGA dataset compared to our mCRC cohort
seems to suggest a higher tendency to cancer progression and
a negative prognostic value to having no detectable pathogenic
mutations, in addition to being less responsive to common
therapies (27). This interesting hypothesis also needs to be
confirmed in independent series.
MAP1.1 patients (as well as MAP1.2, MAP2.1, and MAP2.2
patients) are not eligible for anti-EGFR therapy, due to KRAS
mutations. More in general, therapies directed against single
targets are likely to fail in this group of patients due to
primary resistance, as a consequence of having ≥3 gene
mutations. Appropriate multitarget combinations should instead
be considered for this group, taking advantage of the druggable
mutations detected in each patient. Inhibitors of immune-
checkpoints are effective in MSS patients (52). The presence
of ≥3 pathogenic mutations/tumor in MAP1.1 may suggest
a higher mutation rate (compared to MAP 2.2/4.2), raising
the possibility to test the efficacy of checkpoint inhibitors, in
this subset.
Due to the occurrence of multiple mutations, target driven
drug combinations also need to be considered for MAP2.1.
However, in this subset we noticed the highest frequency of
PIK3CA mutations (42/66), 5/66 PTEN mutations and 3 out
of the 5 AKT1 mutations, mutually exclusive with PIK3CA
mutations. Thus, the highest frequency of constitutive activation
of the PI3K-AKT1 pathway occurs in this TP53WT subset. It has
been shown that p53 may limit KRAS dependent transformation
(53), suggesting that p53 inactivation may be required for KRAS-
dependent cancer development. Nonetheless, KRAS and TP53
mutations are not positively associated in mCRC (31, 44), at
variance with NRAS mutations. Of interest, PI3K-AKT axis
impinges on MDM2, promoting an increased E3-ubiquitin ligase
activity, ultimately leading to p53 functional inactivation via
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increased degradation (54). Therefore, activation of the PI3K-
AKT pathway provides a functional mean to inactivate p53, in
KRAS mutant samples. Consistent with this, Singh et colleagues
found mutually exclusive occurrence of TP53 mutations and
PIK3CA amplification in squamous cell carcinomas (55). This
support the possibility that TP53 reactivation approaches, which
are being tested elsewhere (56), could also find application in
MAP2.1 mCRC (Figure 4).
Beside standard treatment including anti-VEGF, additional
intervention is hard to prospect for MAP1.2 patients, since they
lack targetable gene mutations, with the possible exception of
MEK inhibitors. Mutant TP53 reactivation approaches are yet to
come at the clinical level, but they will find potential application
also in this mCRC subset. The role of immunotherapy in this
subset and in MAP2.2 patients seems counterintuitive, due to the
low mutation rate.
Targeting EGFR as a single strategy will probably be ineffective
for most patients of MAP3.1 due to the frequent occurrence
of PIK3CA, NRAS, BRAF, or SMAD4 mutations, all of which
have been related to primary resistance to this approach (17,
43, 57, 58). Therefore, combination treatments should also be
carefully planned in this subset. Importantly, fewMSI-H patients
fall in this group creating opportunities for immune system
reactivation therapies.
In sharp contrast, MAP3.2 and MAP4.2 patients, largely
coincident with the known “quadruple negative” mCRC subset
(24, 59), are probably themost eligible to chemotherapy plus anti-
EGFR therapies, since they lack known predictable resistance
mechanisms. Of interest, these subsets are prevalent in the left
colon, consistent with the observation that TP53 mutations and
alternative mechanisms of activation of receptor tyrosine kinase
pathways characterize tumors developing in the distal colon
(14). These data also fit with the recently reported increased
chance of response to anti-EGFR treatment in left colon mCRC
(60, 61).
mCRCs of the MAP4.1 subset are predominantly localized
to the right colon, where tumors appear to be less responsive to
conventional therapies (60, 62). In this subset we detected
the highest percentage of BRAFV600E mutant patients,
suggesting multiple targeting of BRAFV600E and EGFR,
perhaps also in combination with MEK inhibitors (50, 63).
Anti-EGFR therapy alone should be possibly avoided, due
to the frequent occurrence of primary resistance mutations
in PIK3CA, NRAS, BRAF, or FBXW7 (17, 43, 57, 58). TP53
reactivation may also seem reasonable, in cases with NRAS
and PIK3CA mutations, similar to MAP2.1 patients. Finally,
MAP4.1 also includes the majority of MSI-H mCRC patients,
which are most likely to benefit from immune checkpoint
inhibitors (52).
Although we are aware that our clinical genomic profiling
does not take into account copy number variations and
genomic rearrangements that may lead to derangement of
specific oncogenic/oncosuppressive pathways, these rarely occur
in mCRC (14). It remains that the major limitation of
our study is that we had no access to homogeneously
collected clinical data, which clearly prevented us from reaching
significant clinical conclusion. In example, we cannot infer
whether any of the MAPs indicates a better response to
anti-VEGF therapy, which is still orphan of biomarkers.
Nonetheless, we believe that the simple and cost-effective
molecular stratification of mCRC compatible with clinical
settings described in this observational study will encourage us
and others to design prospective studies to specifically address its
effective value for more personalized therapeutic intervention of
mCRC patients.
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